Spyre Therapeutics, Inc.
DE ˙ DB ˙ US00773J2024
60,00 € ↑0,50 (0,84%)
2026-06-03
AKTIENPREIS
SecurityDE:3920 / Spyre Therapeutics, Inc.
InstitutionMillennium Management Llc
ManagerIsrael Englander
Latest Disclosed Ownership146,639 shares
Latest Disclosed Value $ 7,396,471
Millennium Management Llc reports 92.45% increase in ownership of 3920 / Spyre Therapeutics, Inc.

On May 15, 2026 - Millennium Management Llc filed a 13F-HR form disclosing ownership of 146,639 shares of Spyre Therapeutics, Inc. (DE:3920) valued at $5,806,904 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 76,194 shares of Spyre Therapeutics, Inc.. This represents a change in shares of 92.45% during the quarter. The current value of the position is $8,798,340 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F SPYRE THERAPEUTICS COM NEW 00773J202 146,639 70,445 92.45 7,396 196.31 0.0031
2026-02-17 2025-12-31 13F SPYRE THERAPEUTICS COM NEW 00773J202 76,194 -332,005 -81.33 2,496 -63.51 0.0010
2025-11-14 2025-09-30 13F SPYRE THERAPEUTICS COM NEW 00773J202 408,199 408,199 6,841 0.0029
2025-05-15 2025-03-31 13F SPYRE THERAPEUTICS COM NEW 00773J202 0 -167,804 -100.00 0 -100.00
2025-02-14 2024-12-31 13F SPYRE THERAPEUTICS COM NEW 00773J202 167,804 167,804 3,906 0.0019
2024-08-14 2024-06-30 13F SPYRE THERAPEUTICS COM NEW 00773J202 0 -319,563 -100.00 0 -100.00
2024-05-15 2024-03-31 13F SPYRE THERAPEUTICS COM NEW 00773J202 319,563 211,077 194.57 12,121 419.32 0.0052
2024-02-14 2023-12-31 13F SPYRE THERAPEUTICS COM NEW 00773J202 108,486 70,673 186.90 2,335 404.10 0.0010
2023-11-14 2023-09-30 13F AEGLEA BIOTHERAPEUTICS COM NEW 00773J202 37,813 37,813 463 0.0002
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.